Involvement of NMDA-nitric oxide pathways in the development of tactile hypersensitivity evoked by the loose-ligation of inferior alveolar nerves in rats.
To investigate whether or not NMDA/nitric oxide (NO) pathways in the trigeminal system are involved in the development and/or maintenance of such pathological pain states as the hyperalgesia and allodynia observed after dental surgery, loose-ligation on the left inferior alveolar nerves of rats were performed. The responses to mechanical stimulation were then measured using von Frey filaments. Hypersensitivity to tactile stimulation developed on the ipsilateral side in ligated animals 5 days after surgery and lasted for at least 30 days. In addition, the effects of drugs on these pain states during the period 2-3 weeks following surgery were investigated. As a result, it was observed that tactile hypersensitivity was inhibited by the intraperitoneal (i.p.) administration of both MK-801 hydrogen maleate (0.05-0.1 mg/kg) and N(G)-monomethyl-L-arginine acetate (L-NMMA: 10-100 mg/kg). Still further, NO production and the number of neuronal NO synthase (nNOS)-positive neurons in the trigeminal nucleus caudalis (SpVc) was evaluated. As a result of these experiments, it was found that the changes in NO levels evoked by the intravenous infusions of N-methyl-D-aspartate (NMDA; 10 mg/kg) and MK-801 (0.5 mg/kg) were significantly larger in the loose-ligated rats compared to the sham-operated rats. Moreover, the number of nNOS-positive neurons was found to have increased on the ipsilateral side in layers I/II of the SpVc. These results would suggest that tactile hypersensitivity develops after inferior alveolar nerve injury and that NMDA receptor/NOS/NO production pathways in the SpVc may be involved in the development of such pathophysiological states.
Yonehara
Norifumi
N
Department of Pharmacology, Osaka University Graduate School of Dentistry, 1-8 Yamadaoka, Suita, 565-0871, Osaka, Japan. yonehara@dent.osaka-u.ac.jp
Kudo
Chiho
C
Kamisaki
Yoshinori
Y
D000818:Animals; D001522:Behavior, Animal / Q000502:physiology; D016291:Dizocilpine Maleate / Q000494:pharmacology; D004566:Electrodes; D007839:Functional Laterality / Q000502:physiology; D006930:Hyperalgesia / Q000503:physiopathology*; D007150:Immunohistochemistry; D008026:Ligation; D008297:Male; D008340:Mandibular Nerve / Q000502:physiology*; D009475:Neurons, Afferent / Q000502:physiology; D009569:Nitric Oxide / Q000378:metabolism / Q000502:physiology*; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052248:Nitric Oxide Synthase Type I; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects; D017729:Presynaptic Terminals / Q000502:physiology; D051381:Rats; D017207:Rats, Sprague-Dawley; D016194:Receptors, N-Methyl-D-Aspartate / Q000502:physiology*; D014275:Trigeminal Caudal Nucleus / Q000503:physiopathology; D019323:omega-N-Methylarginine / Q000494:pharmacology
D016194:Receptors, N-Methyl-D-Aspartate; D019323:omega-N-Methylarginine; D009569:Nitric Oxide; D016291:Dizocilpine Maleate; D019001:Nitric Oxide Synthase; D052248:Nitric Oxide Synthase Type I; C496322:Nos1 protein, rat